Olema Pharmaceuticals (OLMA) Projected to Post Quarterly Earnings on Monday

Olema Pharmaceuticals (NASDAQ:OLMA) is expected to post its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect Olema Pharmaceuticals to post earnings of ($0.63) per share for the quarter.

Olema Pharmaceuticals Price Performance

OLMA opened at $4.61 on Friday. The stock has a market capitalization of $264.14 million, a PE ratio of -2.11 and a beta of 2.11. Olema Pharmaceuticals has a 12-month low of $4.07 and a 12-month high of $16.62. The firm’s fifty day moving average price is $5.35 and its 200 day moving average price is $8.85.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday.

Insider Transactions at Olema Pharmaceuticals

In other news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the stock in a transaction dated Wednesday, January 8th. The stock was acquired at an average price of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the transaction, the insider now owns 7,800,000 shares of the company’s stock, valued at approximately $44,928,000. The trade was a 4.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Cyrus Harmon sold 8,256 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total transaction of $77,358.72. Following the transaction, the director now owns 772,277 shares of the company’s stock, valued at $7,236,235.49. This represents a 1.06 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 773,797 shares of company stock worth $5,414,609. Insiders own 19.40% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.